The Braeburn Group of Schools, a provider of international education in Kenya has advertised vacancies for teaching and ...

Conservation biology is the study of attempts to protect and preserve biodiversity. It focuses on both the biological and social factors that affect the success of conservation efforts and on ...

No Oxular employees are joining Regeneron, though several will be “helping short-term with tech transfer and transition work in consulting roles,” a Regeneron spokesperson told Fierce Biotech ...

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Built by Biology just as Nature intended.” As of Sept. 30, 2024, the company had cash and cash equivalents of $25,297. Last week, the company entered into a securities purchase agreement with ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...

Local biotech Heron Therapeutics is relocating its headquarters from San Diego to North Carolina, where it says the area’s burgeoning biotech scene “provides ample space for growth and ...

Va­lo Health’s di­a­bet­ic retinopa­thy drug failed to im­prove pa­tients’ symp­toms in a Phase 2 study, and the com­pa­ny is now on the hunt for a … ...

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...

One of Australia’s top mining journalists, Kristie Batten writes for Stockhead every week in her regular column placing a watchful eye on the movers and shakers of the small cap resources scene. The ...

New York is the backdrop for famous holiday films such as “Miracle on 34th Street,” “Home Alone 2” and “Elf.” This year came a less felicitous kind when a video appeared of a woman ...

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is ...